25 research outputs found
Analysis of Cannabinoids and Their Metabolites in Human Urine
Biologically monitoring
marijuana exposure from active and passive
use requires both a wide linear range and sensitive detection. We
have developed and validated a multifunctional method using ultrahigh
performance liquid chromatography coupled with tandem mass spectrometry
(UHPLC–MS/MS) for analysis of urinary Δ9-tetrahydrocannabinol
(THC), cannabidiol and cannabinol, and two major metabolites of THC,
11-nor-9-carboxy-THC and 11-hydroxy-THC, in active users and particularly
in people exposed to secondhand marijuana smoke (SHMS). The method
used positive electrospray ionization (ESI) mode to reach the sensitivity
needed to detect trace SHMS exposure with limits of detection (LOD)
ranging from 0.002 to 0.008 nanograms per milliliter (ng/mL) and 0.005
to 0.017 ng/mL for “free” (unconjugated forms) and “total”
(unconjugated plus conjugated forms) measurements, respectively. These
LODs were approximately 10–100 times more sensitive than those
reported in the literature. To reduce or avoid time-consuming repetitive
sample preparation and analysis, the method simultaneously monitored
multiple reaction monitoring transitions in negative ESI mode to quantify
high analyte levels typically found in the urine of active marijuana
users (linear dynamic range of 12.5–800 ng/mL). The validation
results indicated this method was accurate (average inter/intra-day
bias, <10%), precise (inter/intra-day imprecision, <10%), and
fast (6 min run time). In addition, sample preparation throughput
was greatly improved using an automation liquid-handling system, meeting
the needs for potential large-scale population studies
Sensitive Quantification of Cannabinoids in Milk by Alkaline Saponification–Solid Phase Extraction Combined with Isotope Dilution UPLC–MS/MS
Examining the Association between Body Burdens of Harmful Chemicals and Heaviness of Marijuana Smoking
Urinary concentrations of PAH and VOC metabolites in marijuana users
Background: Marijuana is seeing increased therapeutic use, and is the world\u27s third most-popular recreational drug following alcohol and tobacco. This widening use poses increased exposure to potentially toxic combustion by-products from marijuana smoke and the potential for public health concerns.
Objectives: To compare urinary metabolites of polycyclic aromatic hydrocarbons (PAHs) and volatile organic compounds (VOCs) among self-reported recent marijuana users and nonusers, while accounting for tobacco smoke exposure.
Methods: Measurements of PAH and VOC metabolites in urine samples were combined with questionnaire data collected from participants in the National Health and Nutrition Examination Surveys (NHANES) from 2005 to 2012 in order to categorize participants (≥18 years) into exclusive recent marijuana users and nonusers. Adjusted geometric means (GMs) of urinary concentrations were computed for these groups using multiple regression analyses to adjust for potential confounders.
Results: Adjusted GMs of many individual monohydroxy PAHs (OH-PAHs) were significantly higher in recent marijuana users than in nonusers (p\u3c0.05). Urinary thiocyanate (p\u3c0.001) and urinary concentrations of many VOC metabolites, including metabolites of acrylonitrile (p\u3c0.001) and acrylamide (p\u3c0.001), were significantly higher in recent marijuana users than in nonusers.
Conclusions: We found elevated levels of biomarkers for potentially harmful chemicals among self-identified, recent marijuana users compared with nonusers. These findings suggest that further studies are needed to evaluate the potential health risks to humans from the exposure to these agents when smoking marijuana
Urinary Metabolite Levels of Flame Retardants in Electronic Cigarette Users: A Study Using the Data from NHANES 2013–2014
Evaluating the safety of e-cigarettes and making informed judgement about developing potential standards require sufficient scientific evidence. Since e-cigarettes are highly engineered products containing plastic, glass and metal parts, and e-liquids are largely different matrices, many toxic compounds which are not typical hazards for the users of combustible tobacco products (e.g., cigarettes), could exist in e-liquids, and consequently, posing potential health risk to e-cigarette users. We combined the measurements of urinary metabolites of organophosphate flame retardants (OPFRs) with questionnaire data collected in the National Health and Nutrition Examination Surveys (NHANES) from 2013 to 2014, and we compared adjusted geometric means (GM) for each biomarker in e-cigarette users with levels in non-users and users of various tobacco products using multiple regression analyses to adjust for potential confounders. We found diphenyl phosphate (DPhP), bis(1,3-dichloro-2-propyl) phosphate (BDCPP), bis(2-chloroethyl) phosphate (BCEP), and dibutyl phosphate (DBUP) were detected in all e-cigarette users. The adjusted GM of BCEP, the metabolite of tris(2-chloroethyl) phosphate (TCEP), was 81% higher than nonusers (p = 0.0124) and significantly higher than those for both cigarette and cigar users (p < 0.05). The findings in this pilot study suggest that certain OPFRs may present in e-cigarettes as contaminants, and consequently, resulting in higher exposure levels in e-cigarette users compared to nonusers. As we only identified 14 e-cigarette users in the survey, the findings in this study need to be confirmed in future study at a larger scale. A better examination of the types and levels of FRs and their potential contamination sources in e-cigarettes is also needed
Brief Report: Lead Levels in Selected Electronic Cigarettes from Canada and the United States
Few published studies have investigated the presence of lead in the e-liquid of electronic nicotine delivery systems (ENDS). Lead inhalation is associated with increased risk of stroke, heart disease, and other diseases. This study used a novel application of graphite furnace technology to compare the concentration of lead between e-liquids of different packaging and product designs using e-liquids that are or were commercially available in the United States and Canada. Eleven nicotine-free disposable ENDS devices and 12 bottled refill solutions that contained nicotine were purchased from retailers in Canada and the United States between 2015 and 2017. E-liquids extracted from the disposable products and individual containers were analyzed for lead content by graphite furnace using atomic absorption detection. The lead concentration of open-wick ENDS devices ranged from 25.2 ppb to 838.4 ppb, with a standard deviation of 187.4 ppb. None of the bottled e-liquids contained quantifiable levels of lead. This study found that quantifiable levels of lead are present in certain disposable e-cigarette devices, and there is evidence from this study that the design of ENDS devices may contribute to lead exposure. These findings suggest that lead testing should be incorporated into future chemical analyses of ENDS devices
Use of Electronic Cigarettes in Smoke-Free Spaces by Smokers: Results from the 2014–2015 Population Assessment on Tobacco and Health Study
Background: Smoke-free air policies exist to protect users and nonusers from exposure to tobacco smoke. Although electronic nicotine delivery systems (ENDS) may expose passerby to nicotine and particulate matter, few US states regulate indoor use of ENDS. The purpose of this study was to investigate reported rationales for ENDS use and reported ENDS use in public smoke-free places by dual cigarette/ENDS users. Methods: A population of ENDS/cigarette co-users (n = 2051) was drawn from Wave 2 of the Population Assessment of Tobacco and Health (PATH) dataset (2014–2015). Harm reduction beliefs and cessation behavior of co-users were investigated as predictors of ENDS use in public smoke-free places using logistic regression. Results: Fifty-eight percent of dual users reported past 30-day ENDS use in public smoke-free places. Reported use of ENDS to cut down on cigarette smoking (OR: 2.38, 95% CI: 1.86, 3.05), as an alternative to quitting tobacco (OR: 1.71, 95% CI: 1.37, 2.13), or because of belief that ENDS help people to quit cigarettes (OR: 1.52, 95% CI: 1.20, 1.92) were significantly associated with increased odds of ENDS use in smoke-free places. Conclusions: Beliefs that ENDS were useful as cessation tools or posed modified risk to users and nonusers were associated with elevated odds of use ENDS in locations where conventional tobacco is prohibited. Due to limitations in the survey instrument, in-home ENDS use could not be directly assessed in this analysis. However, these self-reported findings suggest that use of ENDS in public places where cigarette use is prohibited is prevalent enough to be of concern for future regulation and enforcement efforts